Inflammatory bowel disease
Drug research and approvals for inflammatory bowel disease: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 560 studies of inflammatory bowel disease are recruiting on ClinicalTrials.gov, and Health Canada has authorized 4 drug trials for it since 2013.
- Recruiting worldwide: 560
- Trials authorized in Canada: 4
- FDA orphan approvals: 0
- EU medicines: 0
- Gut Microbiome Diversity in Adults With Inflammatory and Immune-Mediated Skin DiseasesNCT07944196 · Not reported · Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · starts Apr 11, 2026
- Phase I Trial of Subcutaneous VDJ010 In Healthy Subjects and Patients With Ulcerative ColitisNCT07932691 · Phase 1 · Beijing VDJBio Co., LTD. · starts Aug 9, 2024
- Systemic and Tissue Inflammatory Biomarkers in Acute AppendicitisNCT07926165 · Not reported · Haydarpasa Numune Training and Research Hospital · starts Jul 12, 2026
- Iron Treatment for Iron Deficiency Anemia in Children and Young Adults With Crohn's DiseaseNCT07925450 · Phase 4 · Weill Medical College of Cornell University · starts Sep 13, 2023
- Specific and Novel Approaches to Care of Inflammatory Bowel Disease During Pregnancy: the PREGO StudyNCT07916727 · Not applicable · Austin Health · starts Apr 15, 2026
- Safety, Dosage, and Microbiome Engraftment Study of MGT-006 for Ulcerative Colitis (ROOT Study)NCT07913347 · Phase 1 / Phase 2 · Metagen Therapeutics, Inc. · starts Jul 9, 2026
- Effects Of Periodontal Therapy In Patients With Inflammatory Bowel DiseaseNCT07905859 · Not reported · University of Turin, Italy · starts Mar 3, 2026
- Microencapsulated Sodium Propionate in IBD Microbiota ModulationNCT07883044 · Not applicable · University of Padova · starts Oct 1, 2026
- Impact of Ultra-Processed Food Reduction on Remission Duration in Pediatric Crohn's DiseaseNCT07884045 · Not applicable · University Hospital, Motol · starts Aug 1, 2026
Phase 3 10
- InfliximabTNF-alpha inhibitor
- Iron isomaltoside 1000Supplement
- AdalimumabTNF-alpha inhibitor
- BalsalazideArachidonate 5-lipoxygenase inhibitor
- CholecalciferolVitamin D receptor agonist
- FluconazoleCytochrome P450 51 inhibitor
- UstekinumabInterleukin-12 inhibitor
- BrazikumabInterleukin-23 inhibitor
- MirikizumabInterleukin-23 inhibitor
- Charcoal, activated
Phase 2 12 of 16
- MesalamineArachidonate 5-lipoxygenase inhibitor
- MetforminMitochondrial complex I (NADH dehydrogenase) inhibitor
- FenofibratePeroxisome proliferator-activated receptor alpha agonist
- AtorvastatinHMG-CoA reductase inhibitor
- PentoxifyllineAdenosine A2 receptor antagonist
- AmitriptylineSerotonin transporter inhibitor
- RosiglitazonePeroxisome proliferator-activated receptor gamma agonist
- BudesonideGlucocorticoid receptor agonist
- MinocyclineBacterial 70S ribosome inhibitor
- SecukinumabInterleukin 17A inhibitor
- DapagliflozinSodium/glucose cotransporter 2 inhibitor
- EtrasimodSphingosine 1-phosphate receptor Edg-1 agonist
Phase 1 or earlier 12 of 20
- IzencitinibJanus Kinase (JAK) inhibitor
- AzathioprineAmidophosphoribosyltransferase inhibitor
- ItraconazoleCytochrome P450 51 inhibitor
- AllopurinolXanthine dehydrogenase inhibitor
- ErgocalciferolVitamin D receptor agonist
- EmpagliflozinSodium/glucose cotransporter 2 inhibitor
- VedolizumabIntegrin alpha-4/beta-7 inhibitor
- AmiselimodSphingosine 1-phosphate receptor modulator
- GSK-1070806Interleukin-18 inhibitor
- AlicaforsenIntercellular adhesion molecule-1 mRNA 3'UTR antisense inhibitor
- Vibrio cholerae, live attenuatedBiological vaccine - induces immune response
- GSK2982772Receptor-interacting serine/threonine-protein kinase 1 inhibitor
How its trials ended
1,215 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 191 whose ending is known, 37% met their primary endpoint, 4% missed it and 60% stopped early.
- Completed, result not reported45237%
- Ongoing32927%
- Status unknown24320%
- Met its primary endpoint706%
- Stopped: other or unclear645%
- Stopped: enrollment or feasibility353%
- Missed its primary endpoint71%
- Stopped: sponsor or business decision6<1%
- Stopped: funding4<1%
- Stopped: lack of efficacy3<1%
- Stopped: safety2<1%
| Mar 13, 2026 | A study to evaluate the long-term safety and efficacy of long-acting antibodies as single agents and in combinations in participants with inflammatory bowel…SPY001-001 / SPY002-091 / SPY003-207 | Spyre Therapeutics | Ongoing |
| Aug 1, 2023 | Efficacy and safety of budesonide mmx® and budesonide cr for induction of remission in microscopic colitis: a prospective, randomized, active comparator pilot…Budesonide | Governors of The University of Calgary | Pending |
| Mar 9, 2018 | Naturalistic monitoring of microglial activation in inflammatory bowel disease18F feppa / [11C]-SL25.1188 | Pet Centre Centre for Addiction and Mental Health | Ongoing |
| Oct 1, 2015 | A phase 4, multicenter, open-label study of serum infliximab concentrations and efficacy and safety of dose escalation in pediatric patients with inflammatory…Remicade | Johnson & Johnson | Closed |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA